| First Author | Screpanti I | Year | 1996 |
| Journal | J Exp Med | Volume | 184 |
| Issue | 4 | Pages | 1561-6 |
| PubMed ID | 8879230 | Mgi Jnum | J:35883 |
| Mgi Id | MGI:83326 | Doi | 10.1084/jem.184.4.1561 |
| Citation | Screpanti I, et al. (1996) Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J Exp Med 184(4):1561-6 |
| abstractText | Castleman's disease is a lymphoproliferative disorder thought to be related to deregulated production of IL-6. We have previously shown that mice lacking the trans- acting factor C/EBP beta, a transcriptional regulator of IL-6 and a mediator of IL-6 intracellular signaling, develop a pathology nearly identical to multicentric Castleman's disease, together with increasingly high levels of circulating IL-6. We describe here how the simultaneous inactivation of both IL-6 and C/EBP beta genes prevents the development of pathological traits of Castleman's disease observed in C/EBP beta-deficient mice. Histological and phenotypic analysis of lymph nodes and spleen of double mutant mice did not show either the lymphoadenopathy and splenomegaly or the abnormal expansion of myeloid, B and plasma cell compartments observed in C/EBP beta-/- mice, while B cell development, although delayed, was normal. Our data demonstrate that IL- 6 is essential for the development of multicentric Castleman's disease in C/EBP beta-/- mice. |
